Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
March 15, 2022 07:01 ET
|
Altimmune, Inc
Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million as of December 31, 2021 GAITHERSBURG, Md., March ...
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
March 08, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year...
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
January 31, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
January 03, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2021 06:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
December 13, 2021 06:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today...
Altimmune to Present at Upcoming Investor and Scientific Conferences
November 22, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...
Altimmune to Present at Upcoming Investor Conferences
November 10, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
November 09, 2021 16:01 ET
|
Altimmune, Inc
Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment ...
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
November 03, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial...